Insmed, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for INSM, updated each market day.
INSM AI Sentiment
AI sees no strong directional signal for Insmed, Inc. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Insmed, Inc.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Sector
Exchange
Market Cap
$34,447,844,458
Cap Tier
Employees
1,664
Headquarters
BRIDGEWATER, NJ
Listed Since
June 1, 2000
Website
INSM Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
INSM Volatility
Insmed, Inc. has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
